Payment overview · 2025
General Payments
$150.39
8 reported records · 7 companies
Healthcare provider profile · identity verified
Troy W Geyman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BONNERS FERRY, ID · NPI 1407847379
Verified facts
What the public records show
CMS Open Payments records show Troy W Geyman, M.D. received $150.39 in general payments during 2025 across 8 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.87 | 23.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.61 | 15.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.82 | 13.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.38 | 13.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.32 | 11.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.83 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.56 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.39 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 349 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 81 |
| Losartan Potassium | Losartan Potassium | 213 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 212 | 54 |
| Lisinopril | Lisinopril | 200 | 66 |
| Gabapentin | Gabapentin | 176 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 27 |
| Famotidine | Famotidine | 136 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 129 | 30 |
| Trazodone Hcl | Trazodone Hcl | 126 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 31 |
| Furosemide | Furosemide | 117 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 20 |
| Sertraline Hcl | Sertraline Hcl | 80 | 20 |
| Azithromycin | Azithromycin | 78 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 21 |
| Eliquis | Apixaban | 76 | 12 |
| Bupropion Xl | Bupropion Hcl | 74 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 17 |
| Montelukast Sodium | Montelukast Sodium | 73 | 12 |
| Simvastatin | Simvastatin | 71 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 13 |
| Prednisone | Prednisone | 67 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 17 |
| Meloxicam | Meloxicam | 65 | 18 |
| Metformin Hcl | Metformin Hcl | 64 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 16 |
| Methocarbamol | Methocarbamol | 62 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 14 |
| Potassium Chloride | Potassium Chloride | 55 | 20 |
| Fluconazole | Fluconazole | 54 | 35 |
| Cefuroxime | Cefuroxime Axetil | 50 | 42 |
| Estradiol | Estradiol | 48 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Methylprednisolone | Methylprednisolone | 46 | 40 |
| Atenolol | Atenolol | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Ozempic | Semaglutide | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Lovastatin | Lovastatin | 41 | 11 |
| Baclofen | Baclofen | 40 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 32 |
| Ondansetron Odt | Ondansetron | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 29 |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 11 |
| Carvedilol | Carvedilol | 35 | 11 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 11 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 33 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Nystatin | Nystatin | 33 | 17 |
| Cephalexin | Cephalexin | 32 | 26 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.39 · 8 records | Boehringer Ingelheim Pharmaceuticals, Inc. | COBENFY, INGREZZA, JARDIANCE, MOUNJARO, Ozempic, REXULTI, Rybelsus, WATCHMAN FLX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error